Reproductive and Hormonal Factors and Risk of Ovarian Cancer by Tumor Dominance: Results from the Ovarian Cancer Cohort Consortium (OC3)

Tianyi Huang & Shelley S. Tworoger et al. · 2019-11-12

Abstract

Background:

Laterality of epithelial ovarian tumors may reflect the underlying carcinogenic pathways and origins of tumor cells.

Methods:

We pooled data from 9 prospective studies participating in the Ovarian Cancer Cohort Consortium. Information on measures of tumor size or tumor dominance was extracted from surgical pathology reports or obtained through cancer registries. We defined dominant tumors as those restricted to one ovary or where the dimension of one ovary was at least twice as large as the other, and nondominant tumors as those with similar dimensions across the two ovaries or peritoneal tumors. Competing risks Cox models were used to examine whether associations with reproductive and hormonal risk factors differed by ovarian tumor dominance.

Results:

Of 1,058 ovarian cancer cases with tumor dominance information, 401 were left-dominant, 363 were right-dominant, and 294 were nondominant. Parity was more strongly inversely associated with risk of dominant than nondominant ovarian cancer (Pheterogeneity = 0.004). Ever use of oral contraceptives (OC) was associated with lower risk of dominant tumors, but was not associated with nondominant tumors (Pheterogeneity = 0.01). Higher body mass index was associated with higher risk of left-dominant tumors, but not significantly associated with risk of right-dominant or nondominant tumors (Pheterogeneity = 0.08).

Conclusions:

These data suggest that reproductive and hormonal risk factors appear to have a stronger impact on dominant tumors, which may have an ovarian or endometriosis origin.

Impact:

Examining the associations of ovarian cancer risk factors by tumor dominance may help elucidate the mechanisms through which these factors influence ovarian cancer risk.

Funding
Community Outreach and EngagementThe NYU Women's Health StudyAdministrative CoreNational Cancer Institute Grant UM1 CA186107The Women's Health Study: Infrastructure Support for Continued Cohort Follow-upElucidating Inflammatory and Metabolic Pathways in Obstructive Sleep Apnea DevelopmentWomen's Health Study: Continued Follow-upWomen's Health Study: Continued Follow-UpWomen's Health Study: Infrastructure support for cohort follow-upThe Women's Health Study: Addition of New Data to Maximize its Research ImpactWorld Health Organization Grant 001Environmental and Genetic Risk Factors For Breast Cancer: The Sister StudyCore A: Biospecimen and High-Dimensional Data Management CoreTRIAL OF ASPIRIN AND VITAMIN E IN WOMENLife Course Cancer Epidemiology Cohort in WomenEstablished Investigator Award Anti-Inflammatory Exposures in Cancer PreventionDepartment of Defense Ovarian Cancer Research Grant W81XWH-12-1-0561Australian National Health Medical Research Council Cancer Council Victoria Grant 209057Australian National Health Medical Research Council Cancer Council Victoria Grant 396414Australian National Health Medical Research Council Cancer Council Victoria Grant 1074383Melbourne Collaborative Cohort Study Grant UM1 CA186107Melbourne Collaborative Cohort Study Grant P01 CA87969Nurses' Health Study II Grant UM1 CA176726Nurses' Health Study II Grant UM1 CA182934Community Outreach and EngagementAdministrative CoreEnvironmental and Genetic Risk Factors For Breast Cancer: The Sister StudyEstablished Investigator Award Anti-Inflammatory Exposures in Cancer PreventionWomen's Health Study: Continued Follow-upTRIAL OF ASPIRIN AND VITAMIN E IN WOMENWomen's Health Study: Continued Follow-UpThe Women's Health Study: Addition of New Data to Maximize its Research ImpactWomen's Health Study: Infrastructure support for cohort follow-up

NCI NIH HHS

P30 CA016087

NIEHS NIH HHS

P30 ES000260

NCI NIH HHS

UM1 CA182913

NHLBI NIH HHS

K01 HL143034

NCI NIH HHS

R01 CA047988

NHLBI NIH HHS

R01 HL080467

NCI NIH HHS

U01 CA182913

NHLBI NIH HHS

RC1 HL099355

Intramural NIH HHS

Z01 ES044005

NCI NIH HHS

P01 CA087969

NHLBI NIH HHS

R01 HL043851

NCI NIH HHS

K05 CA154337

Nurses' Health Study II

P30 CA016087

Nurses' Health Study II

P30 ES000260

NIEHS

Z01-ES044005

Swedish Cancer Foundation

K05CA154337

NCI

CA047988

NCI

HL043851

NCI

HL080467

NCI

HL099355

NCI

CA182913